Overview

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Hyaluronic Acid
Ophthalmic Solutions
Tetrahydrozoline
Tofacitinib